Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
Department of Clinical Research, University of Bern, Bern, Switzerland.
Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. doi: 10.1158/1078-0432.CCR-15-2987. Epub 2016 May 16.
Deregulated signaling via the MET receptor tyrosine kinase is abundant in gastric tumors, with up to 80% of cases displaying aberrant MET expression. A growing body of evidence suggests MET as a potential target for tumor radiosensitization.
Cellular proliferation and DNA damage-induced senescence were studied in a panel of MET-overexpressing human gastric cancer cell lines as well as in xenograft models after MET inhibition and/or ionizing radiation. Pathways activation and protein expression were assessed by immunoblotting and immunohistochemistry. Tumor tissue microarrays (91 gastric cancer patients) were generated and copy number alteration (178 patients) and gene expression (373 patients) data available at The Cancer Genome Atlas were analyzed to assess the coalterations of MET and FOXM1.
MET targeting administered before ionizing radiation instigates DNA damage-induced senescence (∼80%, P < 0.001) rather than cell death. MET inhibition-associated senescence is linked to the blockade of MAPK pathway, correlates with downregulation of FOXM1, and can be abrogated (11.8% vs. 95.3%, P < 0.001) by ectopic expression of FOXM1 in the corresponding gastric tumor cells. Cells with ectopic FOXM1 expression demonstrate considerable (∼20%, P < 0.001) growth advantage despite MET targeting, suggesting a novel clinically relevant resistance mechanism to MET inhibition as the copresence of both MET and FOXM1 protein (33%) and mRNA (30%) overexpression as well as gene amplification (24,7%) are common in patients with gastric cancer.
FOXM1, a negative regulator of senescence, has been identified as a key downstream effector and potential clinical biomarker that mediates MET signaling following infliction of DNA damage in gastric tumors. Clin Cancer Res; 22(21); 5322-36. ©2016 AACR.
MET 受体酪氨酸激酶的信号失调在胃肿瘤中非常丰富,高达 80%的病例显示异常的 MET 表达。越来越多的证据表明 MET 是肿瘤放射增敏的潜在靶点。
在一组 MET 过表达的人类胃癌细胞系以及 MET 抑制和/或电离辐射后的异种移植模型中,研究了细胞增殖和 DNA 损伤诱导的衰老。通过免疫印迹和免疫组织化学评估途径激活和蛋白质表达。生成了肿瘤组织微阵列(91 例胃癌患者),并分析了癌症基因组图谱中的拷贝数改变(178 例患者)和基因表达(373 例患者)数据,以评估 MET 和 FOXM1 的协同作用。
在电离辐射之前进行 MET 靶向治疗会引发 DNA 损伤诱导的衰老(约 80%,P < 0.001),而不是细胞死亡。MET 抑制相关的衰老与 MAPK 途径的阻断有关,与 FOXM1 的下调相关,并且可以通过在相应的胃肿瘤细胞中异位表达 FOXM1 来阻断(11.8%对 95.3%,P < 0.001)。尽管对 MET 进行靶向治疗,但具有异位 FOXM1 表达的细胞表现出相当大的(约 20%,P < 0.001)生长优势,这表明存在一种新的临床相关的 MET 抑制耐药机制,因为在胃癌患者中,MET 和 FOXM1 蛋白(33%)和 mRNA(30%)过表达以及基因扩增(24.7%)的共表达很常见。
FOXM1 是衰老的负调节剂,已被确定为关键的下游效应因子和潜在的临床生物标志物,可介导胃肿瘤中 DNA 损伤后的 MET 信号传导。临床癌症研究; 22(21); 5322-36。©2016AACR。